Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Travere Therapeutics Inc (NASDAQ: TVTX) was $33.72 for the day, down -1.20% from the previous closing price of $34.13. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 2.31 million shares were traded. TVTX stock price reached its highest trading level at $34.0 during the session, while it also had its lowest trading level at $32.99.
Ratios:
Our analysis of TVTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.75. In the meantime, Its Debt-to-Equity ratio is 4.48 whereas as Long-Term Debt/Eq ratio is at 4.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on October 31, 2025, Reiterated its Buy rating but revised its target price to $48 from $34 previously.
Citigroup reiterated its Buy rating for the stock on June 11, 2025, while the target price for the stock was revised from $35 to $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 04 ’25 when SANDRA CALVIN bought 67,115 shares for $36.00 per share.
Coughlin Timothy sold 18,000 shares of TVTX for $630,601 on Oct 31 ’25. The Director now owns 55,500 shares after completing the transaction at $35.03 per share. On Oct 31 ’25, another insider, Heerma Peter, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 5,591 shares for $35.00 each. As a result, the insider received 195,685 and left with 119,071 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 3017007104 and an Enterprise Value of 3092225792. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.92 while its Price-to-Book (P/B) ratio in mrq is 41.00. Its current Enterprise Value per Revenue stands at 7.095 whereas that against EBITDA is -88.266.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.90, which has changed by 0.9326161 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $36.15, while it has fallen to a 52-week low of $12.91. The 50-Day Moving Average of the stock is 32.23%, while the 200-Day Moving Average is calculated to be 70.36%.
Shares Statistics:
TVTX traded an average of 2.26M shares per day over the past three months and 2457990 shares per day over the past ten days. A total of 89.46M shares are outstanding, with a floating share count of 87.09M. Insiders hold about 2.66% of the company’s shares, while institutions hold 120.82% stake in the company. Shares short for TVTX as of 1760486400 were 11840340 with a Short Ratio of 5.24, compared to 1757894400 on 12319282. Therefore, it implies a Short% of Shares Outstanding of 11840340 and a Short% of Float of 13.33.
Earnings Estimates
Travere Therapeutics Inc (TVTX) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.13 and low estimates of -$0.09.
Analysts are recommending an EPS of between $1.06 and $0.61 for the fiscal current year, implying an average EPS of $0.83. EPS for the following year is $1.61, with 6.0 analysts recommending between $2.98 and $0.05.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $169M to a low estimate of $122.37M. As of. The current estimate, Travere Therapeutics Inc’s year-ago sales were $74.79MFor the next quarter, 9 analysts are estimating revenue of $125.21M. There is a high estimate of $144.7M for the next quarter, whereas the lowest estimate is $93.7M.
A total of 10 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $545M, while the lowest revenue estimate was $483.41M, resulting in an average revenue estimate of $504.78M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $665.92M in the next fiscal year. The high estimate is $802.8M and the low estimate is $468.83M.
